GKOS ▼ -0.2% - Glaukos Corporation
$GKOS - Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
08-OCT-2026 07:05 AM ET
Share this post
More filings for $GKOS
GKOS ▲ +1.0% - Glaukos CorporationOct 9, 2026GKOS ▲ +8.5% - Glaukos CorporationOct 7, 2026GKOS ▲ +8.5% - Glaukos CorporationOct 7, 2026GKOS ▼ -0.1% - Glaukos CorporationOct 7, 2026GKOS ▲ +0.0% - Glaukos CorporationSep 23, 2026
View full $GKOS filing history →💬 Comments
Loading comments…
Leave a comment